|
 |
|
|||||||
|
|||||||||
© 2005 by the American Diabetes Association, Inc.
Letters: Observations |
Itraconazole-Induced Painful Neuropathy in a Man With Type 1 Diabetes
1 Auckland Diabetes Centre, Auckland, New Zealand
2 Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
Address correspondence to Tim Cundy, MD, Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. E-mail: t.cundy{at}auckland.ac.nz
The antifungal agent itraconazole is considered safe in patients with diabetes (1,2) but has been associated with acute painful neuropathy in patients taking vincristine (3–5). We describe a patient with diabetic neuropathy who developed acute painful neuropathy with itraconazole therapy.
A 37-year-old man with poorly controlled type 1 diabetes of 19 years’ duration presented with an excematous rash affecting his lower abdomen. Skin scrapings grew C. albicans. Itraconazole (200 mg/day) was prescribed, but on the 4th day of treatment he developed acute bilateral leg weakness with stabbing pain in the hips and legs and difficulty walking. He was taking no other medication apart from insulin. He was known beforehand to have peripheral neuropathy with absent ankle reflexes and mild postural hypotension.
On examination, his BMI was 24 kg/m2, his calf muscles were tender, and he had moderate proximal leg weakness. His muscle tone was normal and knee reflexes preserved. There was no change in postural hypotension or sensory abnormalities. Itraconazole was stopped after 7 days. Over the next 6 months his pain improved, although he lost 6 kg in weight. The power in his legs recovered, but the knee reflexes were lost. Over the next year his pain improved and he became asymptomatic.
At the onset of his symptoms, blood count, erythrocyte sedimentation rate, renal function, and serum creatine kinase were normal. On repeated follow-up, these blood tests and his HbA1c remained unchanged. The vibration perception threshold at the medial malleolus rapidly declined over the next year. Nerve conduction studies of the upper and proximal lower limbs were normal, but conduction velocities were slow in the distal lower limbs. Over the next year, the distal lower limb compound muscle action potential amplitudes reduced, sug-gesting loss of these nerve fibers. Electromyography (EMG) was normal at presentation, but after 6 months showed signs of lower-limb muscle denervation. There were no features to support lumbar plexopathy. As the abnormalities were most marked in the distal muscles, this suggests axonal degeneration, which tends to affect the longest nerve fibers first.
There are a number of diagnostic possibilities. Acute painful neuropathy generally occurs within days of rapid improvements in glycemic control, which was not the case in our subject. Diabetic amyotrophy often presents with severe anterior thigh muscle pain and weight loss; however, EMG typically shows evidence of lumbosacral plexopathy (6). Acute diabetic radiculopathy can cause acute pain and weakness, but the symptoms are usually in a single nerve root distribution. Diabetic cachexia can be associated with profound weight loss, symmetrical peripheral neuropathy, and autonomic dysfunction but is generally associated with painful dysesthesias without weakness (7).
In this man with preexisting diabetic neuropathy, the sudden onset of neurological symptoms with itraconazole ther-apy, axonal degeneration on electrophysiological testing, and stabilization after stopping itraconazole suggest that a drug-induced polyneuropathy is the most likely diagnosis. Drug-induced neuropathy is associated with axonal degeneration, lasting weeks or months (8). Discontinuing the administration of the drug does not always lead to improvement, as the damage to neuronal structures or function can be permanent.
References
- Albreski DA, Gross EG: The safety of itraconazole in the diabetic population. J Am Podiat Med Assoc 89:339–345, 1999[Abstract]
- Verspeelt J, Marynissen G, Gupta AK, De Doncker P: Safety of itraconazole in diabetic patients. Dermatology 198:383–384, 1999
- Jeng M, Feusner J: Severe vincristine toxicity potentiated by itraconazole therapy in a child with acute lymphocytic leukemia 21:329–330, 1999
- Sathiapalan RK, El-Solh H: Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature. Pediatr Hematol Oncol 18:543–546, 2001[Medline]
- Bohme A, Ganser A, Hoelzer D: Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol 71:311–312, 1995[Medline]
- Subramony SH, Wilbourn AJ: Diabetic proximal neuropathy: clinical and electromyographic studies. J Neurol Sci 53:293–304, 1982[Medline]
- Blau RH: Diabetic neuropathic cachexia: report of a woman with this syndrome and review of the literature. Arch Intern Med 143:2011–2012, 1983[Abstract]
- Peltier AC, Russell JW: Recent advances in drug-induced neuropathies. Curr Opin Neurol 15:633–638, 2002[Medline]
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Cereda, M. Turrini, D. Ciapanna, L. Marbello, A. Pietrobelli, and E. Corradi Assessing Energy Expenditure in Cancer Patients: A Pilot Validation of a New Wearable Device JPEN J Parenter Enteral Nutr, November 1, 2007; 31(6): 502 - 507. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. St-Onge, D. Mignault, D. B Allison, and R. Rabasa-Lhoret Evaluation of a portable device to measure daily energy expenditure in free-living adults Am. J. Clinical Nutrition, March 1, 2007; 85(3): 742 - 749. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |